期刊文献+

沙美特罗和福莫特罗对腺苷酸环化酶的激活作用 被引量:2

Stimulative effects of salmeterol and formoterol on adenylate cyclase1
下载PDF
导出
摘要 为研究新长效支气管扩张剂沙美特罗和福莫特罗对腺苷酸环化酶的激活作用,以及福莫特罗的受体选择性,运用双柱离子交换层析法测定福莫特罗和沙美特罗作用于牛支气管平滑肌细胞膜和人肺细胞膜,刺激腺苷酸环化酶生成cAMP的效应.结果表明,福莫特罗激活腺苷酸环化酶的内在活性为高效激动剂异丙肾上腺素的97.5%,而沙美特罗仅为81.6%.β2受体拮抗剂ICI118551和沙美特罗均可使福莫特罗生成cAMP的剂量效应曲线向高浓度方向移动,说明福莫特罗为高效激动剂,具有β2受体选择性,而沙美特罗为部分激动剂. To study the stimulative effects of salmeterol and formoterol on adenylate cyclase and the receptor selectivity of formoterol, the cAMP production of calf tracheal smooth muscle membrane and human lung cell membrane was determined with dual column chromatography. The intrinsic activity of formoterol and salmeterol to induce cAMP was found being 97.5% and 81.6% respectively compared to that (100%) of full agonist isoproterenol. β2Receptor antagonist ICI 118551 and salmeterol shifted the dose response curve of formoterol towards the direction of the high doses. Formoterol showed full agonist characteristics, whereas salmeterol showed partial agonist characteristics. Formoterol was β2selective. Salmeterol inhibited the effect of formoterol competitively.
作者 包雅琳
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 1998年第3期210-214,共5页 Chinese Journal of Pharmacology and Toxicology
基金 德国科研机构Le-522/2-1资助
关键词 沙美特罗 福莫特罗 支气管扩张剂 腺苷酸环化酶 bronchodilator receptors, adrenergic intrinsic activity cAMP
  • 相关文献

同被引文献19

  • 1刘春涛,黎联,梁宗安,滕鸿.吸入激素联合长效β_2受体激动剂治疗哮喘6个月疗效观察[J].中国呼吸与危重监护杂志,2004,3(4):241-244. 被引量:18
  • 2陈萍.福莫特罗和沙美特罗治疗支气管哮喘[J].新药与临床,1995,14(6):360-361. 被引量:2
  • 3朱振宏.福莫特罗治疗哮喘急性发作临床分析[J].海峡药学,2005,17(6):123-125. 被引量:1
  • 4Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment[J]. BMJ, 1993,306: 1034-1037
  • 5SMART Study Group. The Salmeterol Muhicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol [J].Chest ,2006,129: 15-26
  • 6Malolepszy J, Boszormenyi Nagy G, Selroos O, et al. Safety of formoterol Turbuhaler at cumulative dose of 90 μg in patients with acute bronchial obstruction [J]. Eur Respir J,2001,18(6): 928-934
  • 7FDA 对沙美特罗提出警告[J].世界临床药物,2003,24(10):577-577.
  • 8Knox AJ. The Scientific Rationale of Combining Inhaled Glucoeorticoids and Long Acting Beta 2 Adrenoeeptor Agonists[J]. Current Pharmaceutical Design, 2002,8(20):1863-1869
  • 9http://www. fdaadvisorycommittee.com/FDC/AdvisoryCommittee/ Committees/ Pulmonary-Allergy+Drugs/071305_betasafety/071305_BroncoP.htm
  • 10Martinez FD. Safety of Long-Acting Beta-Agonists-An Urgent Need to Clear the Air[J]. New England Journal of Medicine ,2005,353(25):2637-2639

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部